Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy
Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Karlin L, Weisel K. Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy. Blood 2023, 142: 1063. DOI: 10.1182/blood-2023-178798.Peer-Reviewed Original ResearchLenalidomide-refractory multiple myelomaPatient-reported outcomesLines of therapyHealth-related qualityDepth of responseMultiple myelomaSOC armCilta-celMM symptomsPRO compliancePrior linesMonth 12PRO scoresLife Questionnaire Core 30EORTC QLQ-C30 domainsGlobal health statusProgression-free survivalDisease-specific symptomsKaplan-Meier methodBaseline PRO scoresVisual analog scaleStandard of careNumber of patientsTotal symptom scaleQLQ-C30 domainsTreatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy
Bair S, Narkhede M, Frosch Z, Chong E, Ermann D, Isufi I, Awan F, Chavez J, Bosma G, Abbott D. Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy. Blood 2023, 142: 68. DOI: 10.1182/blood-2023-187113.Peer-Reviewed Original ResearchReal-world progression-free survivalReal-world overall survivalMultivariate Cox regression analysisR-CHOPAlternative regimensAge 70Partial responseTreatment intensityComplete responseMedian ageElderly ptsMedian Charlson Comorbidity Index scoreMedian real-world overall survivalCharlson Comorbidity Index scoreHigh-risk IPI scoreLarge real-world studyAnthracycline-based chemoimmunotherapyHigh-risk IPIComorbidity Index scoreFirst-line therapyProgression-free survivalKaplan-Meier methodCox regression analysisLong-term outcomesLog-rank test